Completed
Adefovir Dipivoxil Addition to Standard Antiretroviral Therapy for HIV-Infected Patients with CD4 Cell Counts >= 200/mm3
What is being tested
Adefovir dipivoxil
Drug
Who is being recruted
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Over 13 Years
+21 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorGilead Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Patients are randomized to receive either adefovir dipivoxil or placebo daily for 24 weeks, after which all patients will receive open-label drug for an additional 24 weeks. Study drug is administered in combination with a current antiretroviral regimen for the entire 48 weeks. Patients are followed every 4 weeks during the first 24 weeks of study, then every 8 weeks during the last 24 weeks.
Principal SponsorGilead Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
400 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 13 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections
Criteria
9 inclusion criteria required to participate
CD4 count >= 200 cells/mm3
Consent of parent or guardian if less than 18 years old
HIV infection with HIV RNA titer >= 2500 copies/ml (2.5 KEq/ml) plasma
Kaposi's sarcoma is permitted provided patient has not received systemic therapy within the past month
Show More Criteria
12 exclusion criteria prevent from participating
Active, serious infections other than HIV that require parenteral antibiotic or antiviral therapy
Current alcohol or substance abuse that would interfere with compliance
Gastrointestinal malabsorption syndrome or chronic nausea or vomiting that would preclude oral medication
Immunomodulating agents such as systemic corticosteroids, IL-2, or interferons
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 27 locations
Univ of Alabama at Birmingham
Birmingham, United StatesOpen Univ of Alabama at Birmingham in Google MapsEast Bay AIDS Ctr
Berkeley, United StatesKraus Med Partners
Los Angeles, United StatesSan Francisco Gen Hosp
San Francisco, United StatesCompleted27 Study Centers